On February 14, 2014, the Institutional Review Board approved an amendment to our ongoing Canadian study of MDMA-assisted psychotherapy for PTSD. The amended protocol, which includes changes to the MDMA dose condition, was submitted to Health Canada for review on February 14, and to the U.S. Food and Drug Administration on February 6. Subjects are now being screened for this study.